Journal article

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

VA Papadimitrakopoulou, TS Mok, J-Y Han, M-J Ahn, A Delmonte, SS Ramalingam, SW Kim, FA Shepherd, J Laskin, Y He, H Akamatsu, WSME Theelen, W-C Su, T John, M Sebastian, H Mann, M Miranda, G Laus, Y Rukazenkov, Y-L Wu

Annals of Oncology | Published : 2020


BACKGROUND: In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. PATIENTS AND METHODS: Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum-pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS..

View full abstract